Safety Monitoring Recommendations Based on the available clinical trial data, clinicians prescribing orforglipron should: (1) counsel patients about expected GI side effects during dose escalation, (2) follow the recommended dose-titration schedule to minimize GI intolerance, (3) monitor for signs of pancreatitis and discontinue if suspected, (4) assess hepatic and renal function at baseline and periodically, (5) screen for personal or family history of MTC or MEN 2, and (6) review concomitant medications for potential CYP3A-mediated drug interactions
Thirteen (12.5%), eight (7.7%), and nine (8.7%) adverse events were reported during 3 months, 6 months, and 1 year of combination treatment, respectively
Melanotan II is not approved by the MHRA for medicinal or cosmetic use
However, any combination protocol should be approached with caution, and our guide on combining multiple peptides covers the principles of safe stacking
Nevertheless, more data from adequately powered human studies are required for further evaluation of the impact of gut microbiota on thyroid diseases and the potential for possible therapeutic interventions